$TEVA

Roche (RHHBY) and Teva (TEVA) gained FDA approvals for new treatments. Mesa Labs (MLAB) and GSK (GSK) announced job cuts. Labcorp (LH) and AstraZeneca (AZN) made strategic deals. Vir (VIR) partnered with Gilead (GILD) for cancer immunotherapy. Galderma (GALD.SW) to acquire ZO Skin Health for $1.5B. Zealand Pharma (ZEAL.CO) partnered with Generate Biomedicines for AI drug discovery.

Merck diversified its pipeline; USP emphasized supply chain security. FDA approved Teva's Weltruza for schizophrenia. Experts discussed rare disease treatments, AI systems, and FDA's Expedited IND Pilot. CPHI Milan showcased drug formulation and manufacturing advancements.

Mayne Pharma settled a 2020 patent dispute with Teva over Imvexxy, a menopause drug. Teva may launch a generic version by 2032. No financial terms were disclosed. Mayne Pharma CEO called it a foundation for long-term planning.

The FDA approved Teva's Weltruza, a once-monthly schizophrenia treatment. The approval highlights Teva's focus on innovative drug delivery. The FDA's Rare Disease Framework Initiative aims to expedite reviews for rare disease treatments, impacting drug developers and manufacturers.

Corcept Therapeutics (CORT) is challenging the testimony of retired judge Kathleen O’Malley in its ongoing antitrust lawsuit with Teva Pharmaceutical (TEVA). Corcept argues O’Malley’s testimony improperly addresses legal questions for the jury. Teva accuses Corcept of using patent litigation to block generic competition for its drug Korlym, seeking financial compensation and injunctive relief. The trial is scheduled for March 2027, with Corcept denying the allegations.

FDA approved Teva's Weltruza, a once-monthly olanzapine injection for schizophrenia, based on phase 3 trial results. Motivista's CT-155, a digital therapeutic, received clearance for negative schizophrenia symptoms. Neurosterix's NTX-253 completed phase 1 and will enter phase 2. Newron's evenamide faces a US trial hold due to 4 deaths in studies.

Teva's Weltruza, a monthly schizophrenia treatment, received FDA approval. It requires no post-injection monitoring, unlike existing treatments. Teva plans a U.S. launch soon. The approval was based on a phase 3 study showing efficacy and a safety profile similar to oral olanzapine. According to Teva, the approved doses are 318 mg, 425 mg, and 531 mg.

JPMorgan increased its price target for Teva (TEVA) to $50 from $40, maintaining an Overweight rating. The move follows Teva's FDA approval for Weltruza, a drug JPMorgan sees as a significant new opportunity, potentially expanding the long-acting olanzapine market.

The US FDA approved Asahi Kasei's pritelivir for persistent herpes in immunocompromised patients. Teva gained FDA approval for its schizophrenia injection, Weltruza. WHO is investigating a pneumonia case in Russia. US measles cases rose to 4,080. City Therapeutics aims for a $956.3M valuation in its IPO. Philips won a Dutch court case against shareholders. Humana's shares surged after strong 2027 Medicare star ratings.

Two U.K. health bodies have ended partnerships with Teva Pharmaceuticals due to pro-Palestinian pressure, following similar actions by other organizations. The move was encouraged by an NHS doctor who criticized the continued financial ties.